Provided by Tiger Trade Technology Pte. Ltd.

AIM ImmunoTech Inc.

0.2584
+0.00532.09%
Post-market: 0.2567-0.0017-0.66%19:48 EDT
Volume:877.27K
Turnover:227.30K
Market Cap:7.87M
PE:-0.07
High:0.2700
Open:0.2631
Low:0.2540
Close:0.2531
52wk High:2.98
52wk Low:0.1901
Shares:30.44M
Float Shares:28.51M
Volume Ratio:0.71
T/O Rate:3.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9303
EPS(LYR):-30.8884
ROE:-2382.30%
ROA:-82.58%
PB:1.02
PE(LYR):-0.01

Loading ...

Hargreave Hale AIM VCT trims share capital with latest buyback

TIPRANKS
·
Aug 12

AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article

GlobeNewswire
·
Aug 12

Analysts’ Opinions Are Mixed on These Healthcare Stocks: AIM ImmunoTech (AIM) and Schrodinger (SDGR)

TIPRANKS
·
Aug 12

AIM Vaccine Sets August Board Meeting to Approve Interim Results and Consider Dividend

TIPRANKS
·
Aug 12

Unicorn AIM VCT Raises £30.6m and Expands Share Capital Through AIM-Focused Equity Offer

TIPRANKS
·
Aug 12

M.P. Evans Cuts Share Count With Latest Buyback on AIM

TIPRANKS
·
Aug 12

AIM ImmunoTech CEO Urges Biodefense Military Integration

TIPRANKS
·
Aug 11

AIM ImmunoTech Q2 EPS $-0.43

THOMSON REUTERS
·
Aug 10

Press Release: AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen(R) Toward Planned Phase 3 Development in Pancreatic Cancer

Dow Jones
·
Aug 10

AIM ImmunoTech Q2 FY26 Net Loss Widens 35.6% to USD 3.79 Million

Reuters
·
Aug 08

AIM ImmunoTech Signs Manufacturing Pact with Sterling Pharma, Cost Seen at $1.5 Million

Reuters
·
Aug 07

AIM ImmunoTech Expands Manufacturing for Ampligen Clinical Supply

TIPRANKS
·
Aug 07

AIM ImmunoTech - Enters Proposal Agreement with Sterling Pharma Solutions on July 31, 2026 - SEC Filing

THOMSON REUTERS
·
Aug 07

Hargreave Hale AIM VCT Cuts Share Count With Buyback and Cancellation

TIPRANKS
·
Aug 05

IQE Director Bastani Sells 500,000 Shares on AIM

TIPRANKS
·
Aug 05

Puma AIM VCT Plans £20 Million Fundraise with New 2026 Share Offer

TIPRANKS
·
Aug 04

AIM ImmunoTech - Duripanc Primary Endpoint Analysis to Begin December 2026; Topline Results Expected Q1 2027

THOMSON REUTERS
·
Aug 03

AIM ImmunoTech Completes Last Dosing in Phase 2 Duripanc Trial of Ampligen Plus AstraZeneca Imfinzi in Metastatic Pancreatic Cancer

Reuters
·
Aug 03

AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point

GlobeNewswire
·
Aug 03

Unicorn AIM VCT Updates Share Capital and Voting Rights

TIPRANKS
·
Aug 03